Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), a biotech company with a market capitalization of $427 million and currently trading at $24.39, recently reported that Dean Schorno, the company's Executive ...

David A. Santos, Executive Vice President and Chief Commercial Officer at Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), recently sold a portion of his holdings in the company. According to a recent SEC ...

Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 10.05%, which has investors questioning if this is right time to ...

SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer ...

Implementing environmental, social, and governance (ESG) practices has become a non-negotiable prerequisite for any business ...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer ...

Rigel will mail the definitive proxy statement/prospectus to shareholders of record as of the close of business on January 10, 2025. Rigel will hold its Extraordinary General Meeting (the ...

(RTTNews) - Rigel Pharmaceuticals (RIGL) announced the FDA has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes. R289 was previously granted Fast Track ...

First patient enrolled in NIH/NHLBI-sponsored Phase 1 Study of fostamatinib, Rigel's oral SYK inhibitor "Our Phase 1 study evaluating fostamatinib in patients with sickle cell disease is an ...